Vimarsana
Biggest News Aggregation in the World

Page 9 - Acibadem News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Acibadem. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Acibadem Today - Breaking & Trending Today

Hasan Suzer Builds Suzermed into Turkey's Leading Medical Tourism Clinic - Vimarsana News

Hasan Suzer Builds Suzermed into Turkey's Leading Medical Tourism Clinic

As the rise of social media has caused many people across the globe to reassess their relationship with their self-image, men and women alike have begun seeking cosmetic treatments at increased rates to fix their perceived faults.

BOARD MEMBER YEŞIM GÜRA IS THE FIRST IN BELGIUM TO BE AWARDED THE DCRO INSTITUTE CERTIFICATE IN RISK GOVERNANCE® - Vimarsana News

BOARD MEMBER YEŞIM GÜRA IS THE FIRST IN BELGIUM TO BE AWARDED THE DCRO INSTITUTE CERTIFICATE IN RISK GOVERNANCE®

IFC-nominated board member Yeşim Güra, a Turkish national, is the first in Belgium to receive this global distinction.

TPG Capital Asia said to acquire IHH Healthcare's education unit for $300m - Vimarsana News

TPG Capital Asia said to acquire IHH Healthcare's education unit for $300m

Private equity firm TPG Capital Asia is close to buying Malaysian IHH Healthcare’s education unit for about $300 million, Bloomberg reported.

Meta-analysis shows angiotensin receptor blocker use linked to increased risk of cancer - Hospital Healthcare EuropeHospital Healthcare Europe - Vimarsana News

Meta-analysis shows angiotensin receptor blocker use linked to increased risk of cancer - Hospital Healthcare EuropeHospital Healthcare Europe

Angiotensin receptor blocker drugs have been found to be linked with an increased risk of developing cancer, and in particular lung cancer

ARBs and Cancer Risk: New Meta-Analysis Raises Questions Again - Vimarsana News

ARBs and Cancer Risk: New Meta-Analysis Raises Questions Again

The trial-level analysis suggests a dose-response relationship between exposure to angiotensin receptor blockers and the risk for cancer, reawakening previous questions on this issue.